FDA has approved lumacaftor/ivacaftor (Orkambi, Vertex) for the treatment of cystic fibrosis in patients 12 years and older.
Formulary Watch
Latest News
All News
Advertisement
After its proposed acquisition of Humana, Aetna is considering bringing its prescription drug management business in-house, which would mean an end to its contract with CVS Health in 2019.
New data from two phase 2 studies showed ceritinib (Zykadia) shrank tumors in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had received previous treatment with an ALK inhibitor and in those receiving an ALK inhibitor for the first time.
Antibiotics are frequently and often inappropriately prescribed to nursing home residents, according to a new study in JAMA Internal Medicine. These antibiotics pose direct risks to recipients and indirect risks to others residents.
Drug maker Novartis plans to try a new pricing model with some healthcare customers when it launches its heart failure drug LCZ696, an angiotensin receptor neprilysin inhibitor (ARNI).
In a new lawsuit, the U.S. government alleges Novartis paid kickbacks to specialty pharmacies to increase sales of deferasirox (Exjade), which removes excess iron from the blood of patients who receive transfusions, and mycophenolic acid (Myfortic), to prevent rejection of kidney transplants.
The American Society of Clinical Oncology is asking for comments on its ASCO Value Framework, which compares the value of new cancer therapies with established treatments.
Patients with previously-treated metastic colorectal cancer (mCRC) taking regorafenib (Stivarga) experienced progression-free survival of 2.7 months, according to new data presented at the recent ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.
A first-in-class antipsychotic that is a selective serotonin inverse agonist (with no dopaminergic, histaminergic, adrenergic, or muscarinic activity) potentially targeting 5-HT2A receptors, improved Parkinson’s disease psychosis (PDP) with demonstrated safety and tolerability, and without worsening motor Parkinson’s, according to data presented in two posters at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS), in San Diego.
According to the August issue of Consumer Reports, the overuse and misuse of antibiotics is leading to the strengthening and spread of dangerous infections that are becoming resistant to these drugs. Here are four recommendations Consumer Reports has for the medical community.
Advertisement
Overuse and misuse of antibiotics has led to a public health crisis-a crisis we must pay attention to now, according to a report that will be published in the August issue of Consumer Reports.
FDA has approved Aurobindo’s entacapone tablets USP, 200 mg, the generic equivalent to Novartis’ Comtan tablets 200 mg.
As lipid management in the United States under goes transition in response to new guideline recommendations and expanding lipid-lowering therapy options, the Duke Clinical Research Institute (DCRI) announced a new study to better understand contemporary lipid management as well as the beliefs and attitudes of patient and providers regarding cholesterol, cardiovascular risk assessment, and options for lipid treatments.
While sales of Gilead Science’s popular hepatitis C drug, Harvoni, had been performing well for several months, the trend has reversed of late. Hepatitis C drug Sovaldi, also from Gilead, has also hit some bumps in the road – in both the U.S. and China.
FDA has approved cangrelor (Kengreal, The Medicines Company) for reducing the risk of periprocedural thrombotic events in patients undergoing percutaneous coronary intervention.
Antibiotic resistance is a growing problem, both in the United States and across the world. The main driving factors behind antibiotic resistance are the overuse and misuse of antibiotics, according to the Centers for Disease Control and Prevention.
Here are 5 drug categories that may command the most impact on pharma spending in the near future.
Rep. Steve Stivers (R-Ohio) and Rep. Peter Welch (D-Vt.) have re-introduced the Fair Access for Safe and Timely (FAST) Generics Act to what they say will increase consumer access to generic drugs, boost market competition and ultimately save consumers money.
A new, painless “smart insulin patch” lowered blood glucose in a mouse model of type 1 diabetes for up to 9 hours, according to a study published in the Proceedings of the National Academy of Sciences.
More adults than children in the United States now take medication for attention deficit hyperactivity disorder (ADHD), according to new data.
The Institute for Safe Medication Practices (ISMP) is cautioning hospital pharmacists and other healthcare professionals about the intravenous cancer medication fluorouracil.
Global prescription drug sales should reach nearly $1 trillion by 2020, thanks in part to FDA approvals of breakthrough drugs for cancer, hepatitis C and other diseases, a new report finds.
The Food and Drug Administration (FDA) and PatientsLikeMe will work together to determine how patient-reported data can give new insights into drug safety.
Infants and children who are given prescription acid-reducing medications face a substantially higher risk of developing Clostridium difficile infection, according to a study published recently in the online edition of Clinical Infectious Diseases.
Synergy Pharmaceuticals’ drug for chronic idiopathic constipation (CIC) has garnered very positive results in a phase 3 clinical trial, the company reported this week.
Once-weekly dulaglutide is an effective treatment option for patients with type 2 diabetes who need to advance to injectable therapy, according to results from a Japanese study presented at the 2015 American Diabetes Association Scientific Sessions in Boston
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
ALK Testing Strategies and Navigating First-Line Treatment Options in Advanced NSCLC
2
How PBMs are tackling behavioral health
3
ALK-Positive NSCLC: Epidemiology, Prognosis, and the Critical Role of Biomarker Testing
4
Most commercial plans cover SC and IV oncology therapies at parity
5